💊 Omega-3 (Omega-3-acid Ethyl Esters)
A prescription medicine used as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia. It is a combination of ethyl esters of omega-3 fatty acids obtained from fish oils, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The dose is set by the doctor or pharmacist.
In Arabic: إسترات أوميغا-3 الحمضية الإيثيلية
✅ What it is used for
- Adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia
🧪 Active ingredient
The active substance is omega-3-acid ethyl esters; each 1-gram capsule contains at least 900 mg of the ethyl esters of omega-3 fatty acids, predominantly EPA (approximately 465 mg) and DHA (approximately 375 mg). The mechanism of action is not completely understood; potential mechanisms include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal beta-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity.
🌿 Benefits
- Reduces triglyceride levels in adult patients with severe hypertriglyceridemia (greater than or equal to 500 mg/dL) as an adjunct to diet
📝 How to use
- Swallow the capsule whole with meals; do not break open, crush, dissolve, or chew
- Patients should be placed on an appropriate lipid-lowering diet before receiving the capsules and should continue this diet during treatment
- Laboratory studies should be done to ascertain that lipid levels are consistently abnormal before instituting therapy
- Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of medical problems such as diabetes mellitus and hypothyroidism
- Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to considering TG-lowering drug therapy
💊 Dosage forms
- 1-gram transparent soft-gelatin capsules filled with light to pale yellow oil, bearing the designation "LS 423" on one side
⚠️ Common side effects
- Eructation
- Dyspepsia
- Taste perversion
- Constipation
- Gastrointestinal disorder
- Vomiting
- Increased ALT and increased AST
- Pruritus and rash
🚨 Serious — seek medical help
- Anaphylactic reaction
- Hemorrhagic diathesis
- Urticaria
⛔ Do not use if
- Known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters capsules or any of its components
❗ Warnings & precautions
- In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy
- May increase levels of low-density lipoprotein (LDL); monitor LDL levels periodically during therapy
- Use with caution in patients with known hypersensitivity to fish and/or shellfish
- Possible association with more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy
- The effect on the risk for pancreatitis has not been determined
- The effect on cardiovascular mortality and morbidity has not been determined
🔄 Drug interactions
- Omega-3-acids may prolong bleeding time
- Patients taking the capsules and an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically
- Clinical trials have not been done to thoroughly examine the effect of the capsules and concomitant anticoagulants
- Daily coadministration of simvastatin 80 mg with the capsules 4 grams did not affect the extent (AUC) or rate (Cmax) of exposure to simvastatin or its major active metabolite
- Daily coadministration of atorvastatin 80 mg with the capsules 4 grams did not affect AUC or Cmax of exposure to atorvastatin
🤰 Pregnancy
The available data from published case reports and the pharmacovigilance database on the use of the capsules in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal studies, omega-3-acid ethyl esters given orally to female rats prior to mating through lactation did not have adverse effects on reproduction or development at doses 5 times the maximum recommended human dose (MRHD) of 4 grams/day, based on a body surface area comparison, and were not teratogenic at clinically relevant exposures. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
🍼 Breastfeeding
Published studies have detected omega-3 fatty acids, including EPA and DHA, in human milk. Lactating women receiving oral omega-3 fatty acids for supplementation have resulted in higher levels of omega-3 fatty acids in human milk. There are no data available on the effects of omega-3 fatty acid ethyl esters on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for the capsules and any potential adverse effects on the breastfed child.
🧒 Children
Safety and effectiveness in pediatric patients have not been established.
👴 Older adults
A limited number of subjects older than 65 years were enrolled in the clinical trials. Safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years.
🌡️ Storage
Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Protect from light and do not freeze. Keep out of reach of children. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure.
💰 Price & brands in your area
Local prices are currently available for Palestine; more countries are coming. Ask your pharmacist for local price and alternatives.
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
The mechanism of action is not completely understood. Potential mechanisms include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal beta-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. The capsules may reduce the synthesis of TG in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids.
Labeled dosing
The daily dose is 4 grams per day, taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily). In clinical studies, the capsules were administered with meals. Assess TG levels carefully before initiating therapy and identify other causes (e.g., diabetes mellitus, hypothyroidism, medications) of high TG levels and manage as appropriate. Swallow capsules whole; do not break open, crush, dissolve, or chew. Laboratory studies should be performed periodically to measure TG levels during therapy. The dose is set by the doctor or pharmacist.
- In hepatic impairment, monitor ALT and AST periodically
- Monitor LDL levels periodically as they may increase
- Use with caution in patients with known hypersensitivity to fish and/or shellfish
- Possible association with more frequent recurrences of symptomatic atrial fibrillation or flutter, particularly within the first months of therapy
- Monitor periodically patients taking an anticoagulant or other drug affecting coagulation
- Not studied in patients with renal or hepatic impairment
- Pharmacokinetics have not been studied in pediatric patients
- Effect on risk for pancreatitis and on cardiovascular mortality and morbidity has not been determined
🎓 Key points for students
- A combination of ethyl esters of omega-3 fatty acids, principally EPA and DHA, sourced from fish oils
- Each 1-gram capsule contains at least 900 mg of the ethyl esters, including approximately 465 mg EPA and approximately 375 mg DHA
- Indicated as an adjunct to diet to reduce TG levels in adults with severe hypertriglyceridemia (greater than or equal to 500 mg/dL)
- Daily dose is 4 grams, as a single dose or two divided doses; swallow capsules whole with meals
- May prolong bleeding time; monitor patients on anticoagulants or anti-platelet agents
- Store at 20°C to 25°C, protect from light, do not freeze
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
What is omega-3-acid ethyl esters and what does it do?
It is a combination of ethyl esters of omega-3 fatty acids (EPA and DHA) used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (greater than or equal to 500 mg/dL).
How do I take it?
Swallow the capsule whole with meals; do not break open, crush, dissolve, or chew. The dose is set by the doctor or pharmacist.
What are the common side effects?
The most common (incidence greater than 3% and greater than placebo) are eructation, dyspepsia, and taste perversion. Constipation, gastrointestinal disorder, vomiting, increased ALT and AST, pruritus, and rash may also occur.
Does it interact with other medicines?
Omega-3-acids may prolong bleeding time, so patients taking an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.
Can it be used in pregnancy and breastfeeding?
Data in pregnant women are insufficient to identify a drug-associated risk. Omega-3 fatty acids are detected in human milk, and there are no data on effects on the breastfed infant or milk production; consult your doctor.
How should it be stored?
Store at 20°C to 25°C, protect from light, do not freeze, and keep out of reach of children.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2026-02), simplified. Updated: 2026-11-16.